Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician’s insight

Table 1 Selected physicochemical and pharmacokinetic properties of padoporfin and padeliporfin

Parameter	Value
	Padoporfin	Padeliporfin
logP (octanol-water)	1.38[55]	-0.19[55]
Apparent volume of distribution (mL)	10.9[55]	22.12[55]
Alfa half-life (min)	11.86[58]	21.65[55]
Beta half-life (h)	11.3[58]	-
Total body clearance (mL/min)	10.18[58]	20.89[55]
Maximal plasma concentration (mg/L)	119[58]	252[47]
Maximal plasma concentration time (min)	15[58]	22[47]
Plasma LDL binding (%)	330[61]	35[61]
Plasma HDL binding (%)	350[61]	315[61]
Plasma HDP binding (%)	315[61]	380[61]
Standard intravenous drug dose (mg/kg)	2[66]	4[61]
Standard radiation fluence (J/cm)	200[83]	200[66]
Drug-light interval (min)	10[66]	10[66]
Standard irradiation wavelength (nm)	763[66]	753[66]

¹Results obtained for mice with transplanted breast tumor cells after 5 mg/kg intravenous injection;

²Results obtained for healthy mice after 6 mg/kg intravenous injection;

³Results obtained for human protein fractions in vitro. LDL: Low level density lipoprotein; HDL: High density lipoprotein; HDP: High density protein.